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The effects of induced sustained ventricular tachycardia on 
the release of plasma-immunoreactive atrial natriuretic 
peptide were evaluated in 11 adult patients undergoing 
diagnostic electrophysiologic study. Plasma concentrations 
of atrial natriuretic peptide withdrawn from the right 
atrium before and during sustained ventricular tachycardia 
(mean tachycardia cycle length 320 ± 68 ms, duration >30 
s) were determined by radioimmunoassay. Hemodynamic 
measurements included phasic femoral artery blood pres-
sure and mean right atrial blood pressure before and 
during ventricular tachycardia. 
During ventricular tachycardia, atrial natriuretic pep-
tide increased from 93 ± 49 pg/ml to 234 ± 195 pg/ml (p < 
0.05), systolic arterial blood pressure decreased from 120 ± 
16 to 70 ± 23 mm Hg (p < 0.001), diastolic arterial blood 
pressure decreased from 63 ± 8 to 51 ± 16 mm Hg (p = NS) 
and niean right atrial blood pressure increased from 3 ± 1 
to 8 ± 5 mm Hg (p < 0.02). In six patients, all hemody-
namic variables and the atrial natriuretic peptide were 
measured during repeated stimulation protocols to investi-
Recently, there has been widespread interest in the endo-
crine properties of the heart. Specific granules in the mam-
malian atria have been shown to contain atrial peptides (I) 
that play an important role in fluid homeostasis (2-5). The 
development of radioimmunoassays to measure circulating 
immunoreactive atrial natriuretic peptide had led to investi-
gations of the mechanisms and factors regulating the release 
of atrial natriuretic peptide (6-8). It has been reported that 
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gate the effect of ventricular stimulation for ventricular 
tachycardia induction on atrial natriuretic factor release. 
Compared with the values obtained during sinus rhythm, 
there was no significant increase in atrial natriuretic factor 
during ventricular stimulation at a cycle length of 600 ms 
(45 ± 20 versus 52 ± 21 pg/mJ) or at a cycle length of 400 
ms (45 ± 20 versus 57 ± 18 pg/ml). No significant linear 
relation could be found among the changes in mean right 
atrial pressure, systolic arterial blood pressure and the 
increase in atrial natriuretic peptide. 
It is concluded that 1) ventricular tachycardia immedi-
ately increases the plasma concentrations of atrial natri-
uretic peptide; 2) the release of atrial natriuretic peptide in 
acute ventricular tachycardia is not related to changes in 
mean right atrial pressure; 3) it is possible that the high 
plasma concentrations of atrial natriuretic peptide during 
ventricular tachycardia contribute to the hypotension asso-
ciated with ventricular tachycardia. 
(J Am Coil CardioI1988;12:1395-9) 
the secretion of atrial natriuretic peptide is stimulated by 
volume loading (7), atrial distension (8,9) and an increase in 
atrial pressure (8-10). A close relation between atrial pres-
sure and atrial natriuretic peptide has been demonstrated 
(9,11,12), and higher concentrations of atrial natriuretic 
peptide have been found in patients with congestive heart 
failure (11-14). 
Only a few investigators have reported the effects of 
acute arrhythmic disorders on atrial natriuretic peptide. 
Previous investigators (15-18) have mainly concentrated on 
the influence of supraventricular tachyarrhythmia on this 
hormone. One study (i9) reported atrial natriuretic peptide 
levels in seven patients with spontaneous ventricular tachy-
cardia. The purpose of our study was 1) to investigate the 
effects of induced sustained ventricular tachycardia on the 
secretion of atrial natriuretic peptide; and 2) to determine 
whether a relation exists between the concentrations of atrial 
natriuretic peptide and the changes in right atrial pressure. 
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Such a relation has been observed in patients with supraven-
tricular tachycardias and in patients with congestive heart 
failure (11,13,17). 
Methods 
Study patients. There were 11 patients aged 28 to 65 
years (mean 52 ± 13) who were undergoing electrophysio-
logic evaluation for documented or suspected ventricular 
tachycardia. Ten of these patients had documented coronary 
artery disease and one had no detectable heart disease. All 
patients were in New York Heart Association functional 
class I to III (referring to heart failure) and were on a stable 
drug regimen including a converting enzyme inhibitor in one 
patient. In addition, atrial natriuretic factor and hemody-
namic measurements were performed subsequently in six 
other patients without inducible ventricular tachycardia 
(matched for age and left ventricular ejection fraction) during 
programmed ventricular stimulation (repeated 10 times) with 
a basic pacing cycle length of 600 and 400 ms for eight beats. 
Electrophysiologic evaluation. After informed, written 
consent had been obtained, the patients were evaluated 
while in the postabsorptive state. Beta-adrenergic blocking 
agents and antiarrhythmic therapy had been discontinued for 
;:::5 half-lives. The studies were performed in the morning; 
the evening before the evaluation, an intravenous solution of 
5% dextrose in water was infused at a rate of 1,000 mU24 h. 
All other liquid intake was stopped 8 h before the electro-
physiologic study. Two quadripolar electrodes for sensing 
and pacing were inserted percutaneously through the femo-
ral vein and placed in the right atrium and at the region of the 
His bundle or in the right ventricle, with the patient under 
local anesthesia. One USCI 6 catheter was similarly inserted 
with the tip placed at the right atrium for pressure recording 
and atrial natriuretic peptide sampling. Systemic arterial 
blood pressure was recorded from the femoral artery after 
the insertion of an arterial line kit (Argon Medical Corp.). 
After all the lines had been properly placed, the patient was 
given a stabilization period of 15 min. The intracardiac 
signals were filtered at 30 to 500 Hz and simultaneously 
displayed with four surface electrocardiographic (ECG) 
leads (I, II, III, VI) on a multichannel oscilloscope (Elec-
tronics for Medicine VRI6) and recorded with an ink-jet 
recorder (Mingograf Siemens-Elema) at paper speeds of 50 
to 100 mm/s. A magnetic analog tape (Kiowa) was used for 
playback. The right atrial and arterial pressures were proc-
essed through a Statham transducer and recorded in milli-
meters of mercury on a Honeywell strip chart recorder at a 
paper speed of 50 to 100 mmls. Arterial blood pressure and 
right atrial pressure were recorded as both phasic and 
electronically damped mean pressures. For the purpose of 
this study, the atrial pressures are reported only as mean 
values. 
Baseline recordings of right atrial pressure and femoral 
artery blood pressure were done in each patient, and blood 
samples were taken from the right atrium for determination 
of the plasma immunoreactive atrial natriuretic peptide 
concentration. The pressure recordings were repeated ap-
proximately 30 s after the induction of ventricular tachycar-
dia starting with the arterial blood pressure. After the 
pressure recordings were completed, blood samples were 
taken from the right atrium, and attempts were undertaken 
to initiate ventricular tachycardia. In all patients, ventricular 
tachycardia could be induced with pacing at the right ven-
tricular apex with a basic pacing cycle length of 600 or 400 
ms for 8 beats followed by two extrastimuli. Ventricular 
tachycardia could be terminated in all patients by overdrive 
pacing after blood sampling. Blood sampling was finished 
approximately 1 min after the onset of ventricular tachycar-
dia. 
Measurement of atrial natriuretic peptide. The determi-
nations were made according to a recently described method 
(6). The blood samples were placed in chilled tubes contain-
ing EDTA and centrifuged at 4°C for 20 min at 3,000 rpm. On 
the same day, the atrial natriuretic peptide was extracted 
from 500 JLI of plasma by passing it through a "Sep-Pack" 
C-18 cartridge. The eluate was stored at -20°C and assayed. 
within 5 days. Synthetic atrial natriuretic peptide standard 
(atriopeptin III) and antibody agonist 1-28-human atrial 
natriuretic peptide were purchased from Peninsula Labora-
tories, Inc. The tracer was iodine-125-labeled rat atrial 
natriuretic peptide (Amersham). The separation was per-
formed with a second antibody. Sensitivity was 1 pg/assay 
tube and the 50% displacement was 10 pg/assay tube. 
Statistical analysis. All values are reported as mean val-
ues ± SD. The t test for correlated samples (two-tailed) was 
used to analyze the changes in atrial natriuretic peptide and 
hemodynamic data. The relation between variables was 
analyzed by computing the correlation coefficients. The 
differences were considered significant at p < 0.05. 
Results 
Atrial natriuretic peptide and pressures during ventricular 
tachycardia (Table 1, Fig. 1 and 2). Atrial natriuretic peptide 
increased from 93 ± 49 pg/ml during sinus rhythm to 234 ± 
195 pg/ml during sustained tachycardia in the 11 patients (p 
< 0.05). Systolic pressure decreased from 120 ± 16 to 70 ± 
23 mm Hg (p < 0.001) and diastolic pressure from 63 ± 8 to 
51 ± 16 mm Hg (p = NS); mean right atrial pressure 
increased from 3 ± 1 to 8 ± 5 mm Hg (p < 0.05). The mean 
ventricular tachycardia cycle length was 320 ± 68 ms; the 
atrial cycle length was different from the ventricular cycle 
length in all patients. In no patient was 1: 1 ventriculoatrial 
conduction recorded; 2:1 conduction was present in Patients 
1, 6 and 9. 
There was no significant correlation between atrial natri-
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Table 1. Plasma Atrial Natriuretic Peptide Concentrations and Electrophysiologic and Hemodynamic Data in 11 Patients With Induced 
Ventricular Tachycardias 
Sinus Rhythm Ventricular Tachycardia 
Patient AeCI VTCL AeCI 
No. SAP DAP MRAP (ms) ANP ANP SAP DAP MRAP (ms) (ms) 
850 30 41 400 800 
2 890 100 280 300 880 
105 60 720 117 342 70 55 3 370 660 
4 150 60 4 750 120 190 100 60 8 330 AFib 
5 115 65 2 650 142 253 60 40 4 320 600 
6 105 55 2 810 33 55 80 60 2 360 740 
7 115 60 4 630 171 249 80 65 13 290 500 
8 100 80 4 790 43 751 50 40 13 280 400 
9 125 75 3 870 144 160 60 20 15 240 470 
10 125 60 4 910 76 123 30 200 800 
11 140 60 5 880 47 134 105 70 8 430 700 
Mean 120 63 3 795 93 234 70 51 8 320 661 
± SD 16 8 97 49 195 23 16 5 68 167 
AeCL = atrial cycle length during ventricular tachycardia (VT); AFib = atrial fibrillation; ANP = plasma immunoreactive atrial natriuretic peptide, measured 
pg/ml; DAP = diastolic arterial pressure; MRAP = mean right atrial pressure; SAP = systolic arterial pressure; VTCL = cycle length of VT. All pressure 
recordings are expressed in mm Hg. 
uretic peptide concentrations and mean right atrial pressure 
during the ventricular tachycardia (r = 0.33). 
Atrial natriuretic peptide during ventricular stimulation in 
patients without ventricular tachycardia. For these six pa-
tients, atrial natriuretic peptide levels did not increase during 
the stimulation protocol at a cycle length of 600 ms, repeated 
10 times (45 ± 20 versus 52 ± 21 pg/ml) or at a cycle length 
of 400 ms (45 ± 20 versus 57 ± 18 pg/ml), repeated 10 times. 
Systolic arterial pressure during sinus rhythm ranged from 
160 to 165 mm Hg (mean 162 ± 3), diastolic pressure from 60 
to 80 mm Hg (mean 73 ± 11) and the mean arterial pressure 
from 93 to 115 mm Hg (mean 105 ± 11). Mean right atrial 
Figure 1. Effect of ventricular tachycardia (VT) on systolic arterial 
pressure (SAP), diastolic arterial pressure (DAP) and mean right 
atrial pressure (RAP) expressed as the mean value ± SD. C = 












pressure ranged from 0 to 2 mm Hg (mean 0.6 ± 1). During 
a ventricular pacing cycle length of 600 ms, systolic arterial 
pressure ranged from 117 to 147 mm Hg (mean 129 ± 12), 
diastolic pressure from 75 to 80 mm Hg (mean 79 ± 3) and 
mean arterial pressure from 90 to 103 mm Hg (mean 95 ± 6). 
The mean right atrial pressure ranged from 0 to 3 mm Hg 
(mean 1.8 ± 1.5). During a ventricular pacing cycle length of 
400 ms, the systolic arterial pressure ranged from 96 to 117 
mm Hg (mean 107 ± 9), diastolic arterial pressure from 72 to 
80 mm Hg (mean 74 ± 4) and mean arterial pressure from 80 
to 90 mm Hg (mean 85 ± 4). The mean right atrial pressure 
ranged from 0 to 5 mm Hg (mean 2.5 ± 3.6). 
Figure 2. Plasma atrial natriuretic peptide (ANP) concentrations at 
baseline (C) and during ventricular tachycardia (VT) expressed as 
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Discussion 
The main findings of our study are that 1) induced 
ventricular tachycardia leads to a significant increase in 
atrial natriuretic peptide; 2) the release of atrial natriuretic 
peptide into the circulation occurs rapidly; and 3) there is 
only a weak relation between an increase in right atrial 
pressure and release of atrial natriuretic peptide as measured 
in the right atrium. 
Mechanisms of Atrial Natriuretic 
Peptide Release 
The finding of secretory granules in atrial tissue (1), the 
identification of peptides with natriuretic activity in atrial 
extracts (3,7,20) and the measurement of atrial natriuretic 
peptide in humans stimulated the search for the mechanisms 
regulating the secretion of atrial natriuretic peptide. It has 
been shown that graded atrial distension in innervated (8,10) 
and denervated (9) hearts and volume expansion (7,21) lead 
to an increase in circulating atrial natriuretic peptide. High 
concentrations of atrial natriuretic peptide during supraven-
tricular arrhythmia have been demonstrated (15-19). A pos-
itive correlation between atrial natriuretic peptide release 
and increased right atrial pressure due to volume overload 
has been shown (11,12,14,22). 
Ventricular tachycardia. However, in our patients with 
induced ventricular tachycardia, with right atrial blood sam-
ples taken within 1 min after tachycardia induction, we could 
not demonstrate a significant linear relation between an 
increase in mean right atrial pressure or a decrease in 
systolic arterial pressure and an increase in atrial natriuretic 
peptide. For several reasons, ventricular tachycardia repre-
sents a unique condition. 
During ventricular tachycardia, both systolic and dias-
tolic functions are impaired and atrioventricular valve regur-
gitation occurs (23). Doppler echocardiographic studies have 
shown reduced mitral valve blood flow (24). These hemody-
namic changes increase atrial pressure as demonstrated by 
our patients. Increase of atrial pressure and stretching of the 
atria stimulate the release of atrial peptide (7,9,10). The close 
positive relation between right atrial pressure and right atrial 
peptide concentration as shown during ventricular pacing 
(25) could not be demonstrated in our patients. This result 
might be due to a methodologic error, as atrial peptide 
concentrations were sampled from the mid right atrium 
where mixing of blood with high peptide concentration 
(coronary sinus) and of blood with low peptide concentration 
(peripheral venous blood) is not complete. Measurement of 
the left atrial pressure might have shown a closer relation to 
an increase atrial peptide than did the recording of the right 
atrial pressure. Furthermore, an extracardiac origin (26-28) 
of the peptide cannot be excluded. The decline in cardiac 
output affects the kinetics of atrial natriuretic peptide. The 
samples were withdrawn within 1 min after the onset of 
ventricular tachycardia. The mean 2.5-fold increase in atrial 
natriuretic peptide concentration is most likely due to in-
creased secretion; yet the possibility that delayed clearance 
from plasma during ventricular tachycardia may contribute 
to the higher concentrations cannot be excluded. 
Ventricular stimulation. Atrial natriuretic factor levels 
did not increase significantly during the stimulation protocol 
in six matched patients without ventricular tachycardia. It 
thus appears that the repeated ventricular stimulation itself 
had a negligible effect on release of this hormone. 
Atrial tachycardia. Atrial tachycardia is a condition 
known to increase the plasma levels of atrial natriuretic 
peptide (15,17). Therefore, the occurrence of atrial tachycar-
dia during ventricular tachycardia could contribute to the 
observed increase of the peptide during ventricular tachy-
cardia. In fact, atrial fibrillation in Patient 4 arose during the 
induced sustained ventricular tachycardia and the atrial rate 
in Patient 8 increased to 150 beats/min; this patient had the 
highest atrial peptide level recorded in the study. Patients 1, 
6 and 9 had 2: 1 ventriculoatrial conduction, a finding that 
also might have contributed to the increase in peptide levels 
during ventricular tachycardia. However, it is difficult to. 
explain why Patient 9 did not exhibit an increase of the 
peptide concentration despite the increase of mean right 
atrial pressure. 
Natriuresis and polyuria. High doses of atrial natriuretic 
peptide increase natriuresis (3,4). Frequently, polyuria oc-
curs after cessation of paroxysmal supraventricular tachy-
cardia. Some investigators (15,19) have postulated that the 
atrial peptide contributes to the incr~ased diuresis seen after 
supraventricular tachycardia. The hemodynamic changes 
during ventricular tachycardia, however, do not favor diure-
sis. Our study with pacing termination of induced ventricular 
tachycardia within 1 min was not designed to address the 
renal effects of the atrial peptide. Further investigation is 
needed to clarify these effects during ventricular tachycar-
dia. 
Neuroendocrine factors. Atrial peptide and ventricular 
tachycardia show a dynamic and complex interplay with the 
autonomic nervous system. The peptide attenuates the re-
lease of epinephrine and inhibits sympathoadrenal activity 
(29,30). A negative inotropic effect may result (31). The 
decrease in cardiac output during ventricular tachycardia 
may be enforced by the vagomimetic action of the atrial 
peptide (32,33). These effects may be counterbalanced to 
some extent by the release of catecholamines during ventric-
ular tachycardia (34). Further investigatiom are needed to 
document whether the acute release of atrial peptide en-
forces the vicious cycle of sustained ventricular tachycardia 
and hemodynamic compromise. 
A limiting factor of our study is its observational charac-
ter. Further research should examine whether extracardiac 
receptors may be involved in the regul!\tion of atrial natri-
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uretic peptide. The role of the peptide during ventricular 
tachycardia remains to be clarified. 
We thank Diane Dugas for secretarial assistance in the preparation of the 
manuscript. 
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